Biopharma financings in 2023 – at $49.3 billion raised through the third quarter (Q3) – are tracking ahead of, or only slightly behind, several years since 2011, except for the two outlier years of 2020 and 2021 when there was a flurry of investments in response to the COVID-19 pandemic.
Through the third quarter 2023 med-tech firms raised $14.35 billion in financings, down 43.82% from $25.55 billion raised in the same period last year. Money raised is also down from $42.04 billion raised in 2021, $47.61 billion in 2020 and $29.66 billion in the first nine months of 2019.
The BioWorld Biopharmaceutical Index (BBI) has fallen from its highest point this year to close September up 5.91% since the start of the year. BBI was down 3.65% at the end of February, peaked at 7.87% at the end of August, then closed up 5.91% on Sept. 29, tracking higher than both the Nasdaq Biotechnology Index (NBI) and Dow Jones Industrial Average.
Through September 2023, biopharmas raised a total of $49.15 billion, up 7.46% in value from the $45.74 billion raised in the same period last year. Value is down from $93.98 billion raised in 2021 and $104.09 billion in 2020, but up from $42.17 billion raised in 2019 in the same time period.